Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DWY87T
|
|||
| Drug Name |
Inclacumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57, D57.8; ICD-9: 282.5, 282.6] | Phase 3 | [1] | |
| Company |
Pfzer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P-selectin (SELP) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Malaria | ||||
| Staphylococcus aureus infection | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| amb2 Integrin signaling | ||||
| Reactome | Platelet degranulation | |||
| Cell surface interactions at the vascular wall | ||||
| WikiPathways | Human Complement System | |||
| Spinal Cord Injury | ||||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05348915) An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial. U.S.National Institutes of Health. | |||
| REF 2 | Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. Expert Opin Biol Ther. 2022 Nov;22(11):1417-1428. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.